Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 13, 2017. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Transaction Type |
|---|---|---|---|---|
| October 13, 2017 | Ordinary Shares (25p) | £15.2659 | 821 shares | Dividend Re-investment |
Breakdown of Transactions:
- Mrs V A Whyte (Company Secretary): Acquired 55 shares.
- Mr I W Whyte (PCA of Company Secretary): Acquired 407 shares.
- Mrs D Connor (PCA of President, Global Manufacturing & Supply): Acquired 259 shares.
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It solely documents routine share acquisitions resulting from dividend re-investment plans.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions were executed on the London Stock Exchange (XLON) following dividends paid on October 12, 2017.
Investor Verification Checklist
- Verify the total number of shares acquired by insiders (821 shares) against the company's insider trading logs.
- Confirm the share price of £15.2659 aligns with the market price on October 13, 2017.
- Ensure the transactions were correctly classified as dividend re-investments rather than open-market purchases.
- Note that this filing provides no data on the company's overall financial performance for the period.